drugset / Trial / NCT03470961

Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients

NCT03470961

Phase 4 Unknown 45 enrolled Tianjin First Central Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

A single-centre, prospective, observational study to evaluate the safety and efficacy of Polyclonal Antibodies in simultaneous Pancreas Kidney Transplant recipients.

Timeline

Start
2018-03-01
Primary completion
2021-03-01
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Thymoglobulin Protein / enzyme biologic 1.5 mg/kg Intravenous
Comparator Thymoglobulin Protein / enzyme biologic 2 mg/kg Intravenous